Skip to main content
. 2023 Oct 16;9(11):e1549. doi: 10.1097/TXD.0000000000001549

TABLE 2.

Demographics of recipients, living donors, and transplantations (N = 49)

Recipients
Median age at transplantation, y 50 (range, 3–74; IQR, 38–59)
ABO blood group, %
 A 29
 B 10
 AB 6
 O 55
Median BMI, kg/m2 24.5 (range, 13.5–31.9; IQR, 22.1–27.5)
Transplant number, %
 1 65
 2 29
 3 4
 ≥4 2
cPRA, %
 80–100 33
 20–79 49
 0–19 18
Female, % 65
Diagnosis, %
 Polycystic kidney disease 21
 Chronic glomerulonephritis 8
 IgA nephropathy 14
 Renal vascular disease 12
 Diabetes 2
 Congenital renal hypoplasia 6
 Chronic renal failure, cause uncertain 16
 Miscellaneous 21
Induction therapy, %
 Basiliximab 86
 None 14
Immunosuppression, %
 MMF, tacrolimus, steroids 88
 MMF, tacrolimus 8
 Everolimus, tacrolimus, steroids 4
Median waiting time before Tx, total, mo 12.5 (range, 0–109; IQR, 8.8–23.3)
Dialysis before Tx, %
 Preemptive 49
 0–12 mo 14
 13–24 mo 8
 25–36 mo 14
 ≥37 mo 15
Living donors
Median age at donation, y 47 (range, 26–70; IQR, 41–58)
ABO blood group, %
 A 53
 B 10
 AB 4
 O 33
Median BMI, kg/m2 24.8 (range, 20.5–33.6; IQR, 23.9–28.0)
Female, % 47
Relation, %
 Spouse 42
 Sibling 12
 Friend 12
 Son/daughter 10
 Parent 8
 Other relation 8
 Anonymous donor 8
Transplantations
Median CIT, min 329 (range, 60–615; IQR, 223–429)
Broad HLA mismatches, %
 0 HLA-A mismatches 10
 0 HLA-B mismatches 2
 0 HLA-DRB1 mismatches 14
 0 HLA-DQB1 mismatches 53

BMI, body mass index; CIT, cold ischemia time; cPRA, calculated panel-reactive antibody; IgA, immunoglobulin A; IQR, interquartile range; MMF, mycophenolate mofetil; Tx, transplant.